ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
July 26 2023 - 4:15PM
Business Wire
Signs manufacturing agreement to grow and
process algal biomass, enters into distribution agreement for
branded DTC sales of ZivolifeTM
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the
“Company”), a biotech/agtech R&D company engaged in the
development of therapeutic, medicinal and nutritional product
candidates derived from proprietary algal cultures, announces the
commercialization of its proprietary algal biomass as a food or
food ingredient.
ZIVO has engaged an independent distributor, ZWorldwide, Inc.,
who will launch the product, branded ZivolifeTM, with an initial
focus on North America. ZIVO and ZWorldwide are parties to an
exclusive commercial agreement that is expected to result in
ongoing product sales by ZIVO.
ZIVO also announces the signing of a contract manufacturing
agreement with Alimenta Algae SAC (“Alimenta Algae”) to grow and
process the algal biomass at facilities previously utilized by ZIVO
for development in Peru. Alimenta Algae is the microalgae
subsidiary of Grupo Alimenta, a global, multi-generational,
family-run agribusiness with headquarters in Lima, Peru.
“ZivolifeTM is the Company’s first revenue-generating product,
and its commercial availability and the establishment of a cohesive
supply chain marks our entry into the global algae food market.
After years of rigorous R&D and product testing, we’re proud to
make ZivolifeTM available to consumers who are looking for a
sustainable, whole-food product that delivers a wide range of
nutrients that contribute to their overall health. We look forward
to growing the market for ZivolifeTM, launching more products based
on our proprietary algae, and will also continue to aggressively
pursue the opportunities we have in the biotech and pharma
markets,” said John Payne, CEO and Chairman of ZIVO Bioscience.
The global food and beverage microalgae market is projected to
reach $247 million by 2033. The Company’s dried algal powder is a
whole-food entrant into this fast-growing and premium segment. The
rapid growth in demand for plant-based protein sources is being
driven by trends in healthy living, environmental sustainability
and ethical considerations. The target market for ZivolifeTM is
consumers of microalgae and so-called “green drinks” who would
benefit from a whole-food supplement to their diet, as well as
conscious consumers who value sustainable products with exceptional
nutritional profiles.
“ZWorldwide is delighted to partner with ZIVO Bioscience to
bring ZivolifeTM to market for the first time. This is a premium
product in the microalgae market as ZivolifeTM is a proprietary
algae strain. Consumers are increasingly looking for nutrient-dense
whole foods to supplement their diets. With our team’s expertise in
DTC sales, e-commerce and brand marketing we are looking forward to
helping grow this exciting category in cooperation with ZIVO,” said
Greg Consiglio, Chairman of ZWorldwide.
“Alimenta Algae is looking forward to bringing our international
agriculture expertise to support the scaleup of ZivolifeTM. Our
prior experience with microalgae along with our commitment to food
quality and safety will ensure that ZivolifeTM is a high-quality,
premium product,” said Vasco Masias, President of Grupo Alimenta
and Alimenta Algae, SAC. “Alimenta Algae has worked extensively
with microalgaes through its pursuit of sustainable superfoods, and
believes this partnership with ZIVO will bring much-needed products
to the food market.”
ZivolifeTM is natural, non-GMO and a source of plant-based
protein, naturally occurring beta glucan and fiber. ZIVO’s dried
microalgae is a source of essential amino acids, polyphenols, iron,
potassium and vitamins A, E and B12. ZivolifeTM supports digestive
and gut health and helps to support a healthy immune system. It has
a mild taste compared with other microalgae and has been tested as
shelf stable for up to two years. ZivolifeTM is 100% made from
ZIVO’s proprietary microalgae. For more information about
ZWorldwide and ZivolifeTM, please visit www.zivo.life.
ZivolifeTM is cultivated at a single-source, sustainable
aquaculture facility in the foothills of the Peruvian Andes
Mountains using proprietary cultivation processes developed in
partnership with ZIVO. The partnership has established
quality-control testing at facilities in Ica, Peru, Ft. Myers,
Florida and certified third-party laboratories. ZivolifeTM will
initially be available in limited quantities as ZIVO scales up
production. For more information about Grupo Alimenta, please visit
www.alimenta.pe.
The revenue received under the agreements described in this news
release is expected to fund ZIVO’s ongoing development of
therapeutic and pharmaceutical product candidates. ZIVO Bioscience
is currently working to complete its latest coccidiosis treatment
study in broiler chickens as part of its efforts to secure a
corporate partnership for this application.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward-Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Although ZIVO believes
that we have a reasonable basis for each forward-looking statement,
we caution you that these statements are based on a combination of
facts and factors currently known by us and our expectations of the
future, about which we cannot be certain. Our actual future results
may be materially different from what we expect due to factors
largely outside our control, including risks that our strategic
partnerships may not facilitate the commercialization or market
acceptance of our products; risks that our products may not be
ready for commercialization in a timely manner or at all; risks
that our products will not perform as expected based on results of
our pre-clinical and clinical trials; our ability to raise
additional funds; uncertainties inherent in the development process
of our products; changes in regulatory requirements or decisions of
regulatory authorities; the size and growth potential of the
markets for our products; the results of clinical trials, our
ability to protect our intellectual property rights and other
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230726035045/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com
LHA Investor Relations Tirth T. Patel (212) 201-6614
tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Oct 2023 to Oct 2024